Leukemia cutis can happen when leukemia cells enter your skin. This rare condition causes patches of discolored skin to appear on the body.
In some cases, the appearance of leukemia cutis lesions on the skin is the first sign of leukemia a cancer of the blood and bone marrow.
Along with standard leukemia therapies, this complication can usually be addressed with topical treatments to help heal the damaged skin. If you have leukemia cutis, your outlook will usually depend on your age and the type of leukemia you have.
Leukemia cutis is an uncommon complication, affecting only about 3 percent of people with leukemia. However, it is often a sign that the cancer is at an advanced stage.
With leukemia, malignant leukocytes (white blood cells) are usually only present in the bloodstream. In the case of leukemia cutis, the leukocytes have entered the skin tissue, causing lesions to appear on the outer layer of your skin. The word cutis refers to the skin, or dermis.
Generally, leukemia cutis results in one or more lesions or patches forming on the outer layer of skin. This condition can mean that the leukemia is more advanced and may have spread to your bone marrow and other organs.
Because there are fewer healthy white cells to combat infections caused by other diseases, rashes and sores may be more common among people with leukemia. Low blood platelets from leukemia can cause damage to blood vessels that appear as red spots or lesions on the skin.
These may include:
However, these skin changes are different than those brought on by leukemia cutis.
While the legs are the most common area for leukemia cutis lesions to appear, they can also form on the arms, face, trunk, and scalp. These skin changes can include:
The lesions usually dont hurt. However, with certain types of leukemia particularly acute myeloid leukemia (AML) the lesions may bleed.
A dermatologist may initially diagnose leukemia cutis based on a physical examination of the skin and a review of your medical history. A skin biopsy is needed to confirm the diagnosis.
Leukemia cutis is a sign of leukemia. It wont develop if the body isnt already dealing with this type of blood cancer.
But leukemia isnt just one disease. There are multiple types of leukemia, each one classified by the kind of cell affected by the disease.
You can also have an acute or a chronic form of leukemia. Acute means it comes on suddenly and usually with more severe symptoms. Chronic leukemia develops more slowly and often with milder symptoms.
The types of leukemia that most commonly trigger leukemia cutis are AML and chronic lymphocytic leukemia (CLL).
Scientists arent sure why cancerous leukocytes migrate to skin tissue in some people with leukemia. It may be that the skin is an optimal environment for healthy leukocytes to transform into cancerous cells.
One possible risk factor that has emerged is an abnormality in chromosome 8, which has been found more often in individuals with leukemia cutis than in those without it.
Treating leukemia cutis usually includes treatment for leukemia as the underlying condition.
The standard leukemia treatment is chemotherapy, but other options may be considered depending on your overall health, your age, and the type of leukemia you have.
Other leukemia treatment options include:
For blood cancers, external beam radiation is a typical form of treatment. With this therapy, a focused beam of radiation is delivered outside the body from various angles. The goal is to injure the DNA in cancer cells to stop them from reproducing.
Immunotherapy, a type of biological therapy, uses the bodys own immune system to fight cancer. It is typically given by an injection that either stimulates immune system cells activity or blocks the signals cancer cells send to suppress the immune response.
Immunotherapy may also be given orally, topically, or intravesically (into the bladder).
Stem cell transplantation is more commonly known as a bone marrow transplant. Bone marrow is where blood stem cells develop. Stem cells can become any type of cell.
Through stem cell transplantation, healthy blood stem cells replace stem cells damaged by the cancer or by chemotherapy or radiation therapy. However, not everyone is a good candidate for this treatment.
Only treating the leukemia cutis lesions will not address the underlying disease of leukemia. That means treatments designed to remove or reduce lesions should be done in combination with systemic treatment for leukemia itself.
Treatments for leukemia cutis symptoms can include:
Again, these treatments will only treat the leukemia cutis lesions, but systemic treatment of the leukemia itself will be needed as well.
The length of time leukemia cutis lesions may last depends on many factors, including how well the leukemia itself is responding to treatment. If the leukemia goes into remission, its unlikely more lesions will appear.
With effective treatment, existing lesions could fade. However, other factors, including your age and overall health, can affect how widespread the lesions are and how long they may last.
There are encouraging trends in the treatment of leukemia, but it remains a challenging disease to treat and live with.
For people with AML who dont have leukemia cutis, research suggests that the survival rate at 2 years is about 30 percent. However, the survival rate drops to 6 percent among people with the skin lesions.
A separate study of 1,683 people with AML found that leukemia cutis was associated with a poor prognosis, and that those with AML and leukemia cutis may benefit from more aggressive treatment.
The outlook for people with CLL is better, with about an 83 percent survival rate at 5 years. The presence of leukemia cutis doesnt seem to change that outlook very much, according to a 2019 study.
Leukemia cutis is a rare complication of leukemia. It happens when malignant leukocytes invade the skin and cause lesions on the skins outer surface.
AML and CLL are more often associated with leukemia cutis than other types of leukemia.
While leukemia cutis usually means the leukemia is in an advanced stage, there are treatments for both the cancer and this uncommon side effect that may help extend life and improve its quality.
- FDA Responds to Creative Medical Technology Holdings Regarding Its ImmCelz IND for Stroke Treatment - KPVI News 6 - May 14th, 2021
- Duluth health center specializes in regenerative medicine, hormone replacement therapy - Duluth News Tribune - May 14th, 2021
- Dr. Krger on Toxicities Associated With Allogeneic Stem Cell Transplant in Myeloma - OncLive - May 14th, 2021
- Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its... - May 14th, 2021
- Genenta Phase I/II Glioblastoma Data at ASGCT Show Temferon Delivered Tumor-Focused Interferon ExpressionData presented at the 2021 American Society... - May 14th, 2021
- ViaCyte To Participate In World Medical Innovation Forum Panel On Future Of Cell Therapy For Type 1 Diabetes - PRNewswire - May 14th, 2021
- Omeros' Narsoplimab Pivotal Trial Data to Be Shared as an Oral Presentation at the European Hematology Association Congress - Business Wire - May 14th, 2021
- Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May - Business Wire - May 14th, 2021
- Outlook for multiple myeloma: Figures and factors that affect it - Medical News Today - May 14th, 2021
- Global Regenerative Medicine for Cartilage Market Report 2021: Companies are Continuously Focusing on Introducing New Technologies to Survive in the... - May 14th, 2021
- UB celebrates 175th anniversary of its origins in study of medicine - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter - May 14th, 2021
- Stem cell therapy for COVID-19 and ARDS - News-Medical.Net - May 7th, 2021
- Experimental COVID-19 lung treatment being tested at Ontario hospitals - CityNews Toronto - May 7th, 2021
- EP. 4: Optimizing Patient Selection for CAR T-Cell Therapy - OncLive - May 7th, 2021
- Could stem cells improve the outcome of ARDS in severe COVID-19? - News-Medical.Net - May 7th, 2021
- Motixafortide Reaches Primary End Point of Improved Stem Cell Mobilization in Multiple Myeloma Trial - Cancer Network - May 7th, 2021
- Restricting the Growth and Spread of Head and Neck Cancers - Technology Networks - May 7th, 2021
- The global stem cell therapy market is projected to reach USD 401 million by 2026 from - GlobeNewswire - May 7th, 2021
- UCLA team discovers how to restrict growth, spread of head and neck cancers | UCLA - UCLA Newsroom - May 7th, 2021
- NUS scientists found a key element that affects how genes are expressed in blood stem cells - Newswise - May 7th, 2021
- Citius Pharmaceuticals to Present Mino-Lok and COVID-related Respiratory Treatment Update at Benzinga Global Small Cap Conference on Thursday, May 13... - May 7th, 2021
- Mesoblast says its stem cell treatment saved lives of severely ill COVID patients - Stockhead - May 2nd, 2021
- Antiviral T cells safe, effective as off-the-shelf therapy for painful complication after stem cell transplants - News-Medical.Net - May 2nd, 2021
- Antiviral T cells protected, viable as off-the-shelf treatment for painful complication stem cells - Microbioz India - May 2nd, 2021
- Desperate family of boy, 9, with leukaemia have 10 days to save his life... - The Sun - May 2nd, 2021
- Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy - GlobeNewswire - May 2nd, 2021
- Investigating CAR T-Cell Therapy for Use in Different Disease Types - Targeted Oncology - May 2nd, 2021
- Enhanced inhibition of tumor growth using TRAIL-overexpressing adipose-derived stem cells in combination with the chemotherapeutic agent CPT-11 in... - May 2nd, 2021
- Thomas Smeenk on Hemostemix's autologous stem cell therapy technology and why some call it 'the fountain of youth' - InvestorIntel - April 28th, 2021
- Monitoring levels of vimentin-positive circulating cancer stem cells and tumor cells in patients with advanced EGFR-mutated non-small cell lung cancer... - April 28th, 2021
- Fate Therapeutics Announces Four Presentations at the 2021 ASGCT Annual Meeting - GlobeNewswire - April 28th, 2021
- Therapeutic Solutions International Reports Regression of Established Tumors by Combining its Cancer Blood Vessel Targeting Immunotherapy with Low... - April 28th, 2021
- A review of baculovirus vectors in gene therapy | BTT - Dove Medical Press - April 28th, 2021
- Stem Cell Therapy for COPD: Hope and Exploitation - DocWire News - April 26th, 2021
- Axion BioSystems Announces Formation of Scientific Advisory Board - Business Wire - April 26th, 2021
- Global Cell Therapy Market By Therapy Type, By Therapeutic Area, By End User, By Cell Type, By Regional Outlook, Industry Analysis Report and... - April 24th, 2021
- Pure Red Cell Aplasia following ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation: Resolution with Daratumumab Treatment - DocWire... - April 24th, 2021
- Advancing the Development of Safe and Effective Regenerative Medicine Products | FDA - FDA.gov - April 24th, 2021
- New method helps map the specialized diversity and spatial location of cells within a tissue or tumor - News-Medical.Net - April 24th, 2021
- Chimeric embryo may have medical implications The Campus - The Campus - April 24th, 2021
- Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France - a cohort study using the French National... - April 24th, 2021
- Guenther Koehne, MD, Highlights Recent Advancements in the Treatment of Blood Cancers - Oncology Learning Network - April 24th, 2021
- Rinri Therapeutics raises 10 million to advance stem cell therapy for hearing loss - The Star - April 24th, 2021
- Cancer Diagnosis in Patient Given LentiGlobin Revised to Severe Anemia - Sickle Cell Anemia News - April 24th, 2021
- Hodgkin lymphoma: Symptoms, outlook, treatment, and more - Medical News Today - April 24th, 2021
- Tissue Repair, Mitochondrial Function and Wound Healing Explored in 2021 APS Presidents Symposium - Newswise - April 24th, 2021
- Axion BioSystems Announces Formation of Scientific Advisory Board - BioSpace - April 20th, 2021
- Avalon GloboCare is seeking to tap the power of cells to fight cancer and coronavirus - Proactive Investors USA - April 20th, 2021
- Rinri Therapeutics Raises 10 million from Existing Investors and UK Future Fund to Advance its Novel Stem Cell Therapy to Restore Hearing Loss -... - April 20th, 2021
- Global Regenerative Medicines Market 2020-2030: Opportunities in Drug Approvals and Strong Pipeline of Cell and Gene Therapies & Multiple... - April 20th, 2021
- FDA Grants Orphan Drug Status to Novel IRAK4 Inhibitor in AML and MDS - Targeted Oncology - April 20th, 2021
- Vertex Drops $900 Million to Expand Partnership with CRISPR Therapeutics - BioSpace - April 20th, 2021
- Kaleido Biosciences Announces Collaboration with Robert Jenq, MD, to Explore Potential of its Microbiome Metabolic Therapies (MMT) in Preventing... - April 20th, 2021
- Partner Content | Being bionic: the future of regenerative medicine - TheSpec.com - April 14th, 2021
- Ohio State Recruits Top Oncologist to Expand Cell Therapy Program, Lead Bone Marrow Transplant Services - Wexner Medical Center - The Ohio State... - April 14th, 2021
- Green: Variants and outbreaks continue to put stress on hospitals - Vermont Biz - April 14th, 2021
- CRISPR Therapies Pipeline Insights 2021: Analysis of Key Companies, Emerging Therapies, Recent Happenings and Futuristic Trends - GlobeNewswire - April 14th, 2021
- Consortium to investigate role of neurofilament light chain in neurodegenerative diseases Washington University School of Medicine in St. Louis -... - April 14th, 2021
- Man's heart healed by stem cell therapy and love of an old flame - Leeds Live - April 12th, 2021
- New pediatric cancer treatment method being used in Iran - Tehran Times - April 12th, 2021
- Personalized Cancer Vaccine Shows Early Efficacy in Patients With Diverse Tumor Types - Technology Networks - April 12th, 2021
- 1000th Stem Cell Transplant Given to Girl Who Is One in a Million - Stanford Children's Health Blog - Stanford Children's Health - April 10th, 2021
- Home : Stem Cell Treatments - April 10th, 2021
- Researchers discover unique regenerative property of cells in the early human embryo - News-Medical.net - April 10th, 2021
- Study reveals sex-differences in aging of the brain stem cell niche - News-Medical.net - April 10th, 2021
- Antibiotics need further study in cancer treatments - Chicago Daily Herald - April 10th, 2021
- Prolonged infection and inflammation drain immune responses as we age - Baylor College of Medicine News - April 10th, 2021
- Toward a transformative therapy for sickle cell patients - News-Medical.Net - April 10th, 2021
- Mass. Residents 55+ Or With 1 Medical Condition Can Now Get COVID Vaccine | WBZ NewsRadio 1030 - iHeartRadio - April 6th, 2021
- Mortality from Multiple Myeloma Within One Year Following Autologous Stem Cell Transplantation: Defining an Ultra-high Risk Population - DocWire News - April 6th, 2021
- BioRestorative Therapies Announces Appointment of Nickolay V. Kukekov, Ph.D to its Board of Directors - BioSpace - April 6th, 2021
- LGL Leukemia: Overview, Symptoms, and Treatment - Healthline - April 3rd, 2021
- Novel T-Cell Therapy MT-401 Under Evaluation in Post-Transplant AML - OncLive - April 3rd, 2021
- Funding the Next Generation of Cancer Therapies - Genetic Engineering & Biotechnology News - April 3rd, 2021
- Do Therapies for Alzheimer's & Parkinson's that Clear Abnormal Brain Proteins Make the Diseases Worse? - BioSpace - April 3rd, 2021
- Allogeneic hematopoietic stem cell transplantation for therapy-related myeloid neoplasms following treatment of a lymphoid malignancy - DocWire News - April 1st, 2021
- Insulin 100: How the road to a diabetes cure is yielding better treatments - News@UofT - April 1st, 2021
- The Government's Watchful Eye on Fraud Stemming from Stem Cell Therapy - Lexology - April 1st, 2021
- Introducing a neuro regenerative gene into mice with spinal cord injury improves motor function - News-Medical.net - April 1st, 2021
- Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy... - April 1st, 2021